Cargando…

Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar

BACKGROUND: The emergence of artemisinin-resistant Plasmodium falciparum parasites in Southeast Asia threatens global malaria control efforts. One strategy to counter this problem is a subsidy of malaria rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT) within the informa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ingrid T, Aung, Tin, Thant, Hnin Nwe Nwe, Sudhinaraset, May, Kahn, James G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334415/
https://www.ncbi.nlm.nih.gov/pubmed/25653121
http://dx.doi.org/10.1186/s12936-015-0569-7
_version_ 1782358184379285504
author Chen, Ingrid T
Aung, Tin
Thant, Hnin Nwe Nwe
Sudhinaraset, May
Kahn, James G
author_facet Chen, Ingrid T
Aung, Tin
Thant, Hnin Nwe Nwe
Sudhinaraset, May
Kahn, James G
author_sort Chen, Ingrid T
collection PubMed
description BACKGROUND: The emergence of artemisinin-resistant Plasmodium falciparum parasites in Southeast Asia threatens global malaria control efforts. One strategy to counter this problem is a subsidy of malaria rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT) within the informal private sector, where the majority of malaria care in Myanmar is provided. A study in Myanmar evaluated the effectiveness of financial incentives vs information, education and counselling (IEC) in driving the proper use of subsidized malaria RDTs among informal private providers. This cost-effectiveness analysis compares intervention options. METHODS: A decision tree was constructed in a spreadsheet to estimate the incremental cost-effectiveness ratios (ICERs) among four strategies: no intervention, simple subsidy, subsidy with financial incentives, and subsidy with IEC. Model inputs included programmatic costs (in dollars), malaria epidemiology and observed study outcomes. Data sources included expenditure records, study data and scientific literature. Model outcomes included the proportion of properly and improperly treated individuals with and without P. falciparum malaria, and associated disability-adjusted life years (DALYs). Results are reported as ICERs in US dollars per DALY averted. One-way sensitivity analysis assessed how outcomes depend on uncertainty in inputs. RESULTS: ICERs from the least to most expensive intervention are: $1,169/DALY averted for simple subsidy vs no intervention, $185/DALY averted for subsidy with financial incentives vs simple subsidy, and $200/DALY averted for a subsidy with IEC vs subsidy with financial incentives. Due to decreasing ICERs, each strategy was also compared to no intervention. The subsidy with IEC was the most favourable, costing $639/DALY averted compared with no intervention. One-way sensitivity analysis shows that ICERs are most affected by programme costs, RDT uptake, treatment-seeking behaviour, and the prevalence and virulence of non-malarial fevers. In conclusion, private provider subsidies with IEC or a combination of IEC and financial incentives may be a good investment for malaria control. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0569-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4334415
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43344152015-02-20 Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar Chen, Ingrid T Aung, Tin Thant, Hnin Nwe Nwe Sudhinaraset, May Kahn, James G Malar J Research BACKGROUND: The emergence of artemisinin-resistant Plasmodium falciparum parasites in Southeast Asia threatens global malaria control efforts. One strategy to counter this problem is a subsidy of malaria rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT) within the informal private sector, where the majority of malaria care in Myanmar is provided. A study in Myanmar evaluated the effectiveness of financial incentives vs information, education and counselling (IEC) in driving the proper use of subsidized malaria RDTs among informal private providers. This cost-effectiveness analysis compares intervention options. METHODS: A decision tree was constructed in a spreadsheet to estimate the incremental cost-effectiveness ratios (ICERs) among four strategies: no intervention, simple subsidy, subsidy with financial incentives, and subsidy with IEC. Model inputs included programmatic costs (in dollars), malaria epidemiology and observed study outcomes. Data sources included expenditure records, study data and scientific literature. Model outcomes included the proportion of properly and improperly treated individuals with and without P. falciparum malaria, and associated disability-adjusted life years (DALYs). Results are reported as ICERs in US dollars per DALY averted. One-way sensitivity analysis assessed how outcomes depend on uncertainty in inputs. RESULTS: ICERs from the least to most expensive intervention are: $1,169/DALY averted for simple subsidy vs no intervention, $185/DALY averted for subsidy with financial incentives vs simple subsidy, and $200/DALY averted for a subsidy with IEC vs subsidy with financial incentives. Due to decreasing ICERs, each strategy was also compared to no intervention. The subsidy with IEC was the most favourable, costing $639/DALY averted compared with no intervention. One-way sensitivity analysis shows that ICERs are most affected by programme costs, RDT uptake, treatment-seeking behaviour, and the prevalence and virulence of non-malarial fevers. In conclusion, private provider subsidies with IEC or a combination of IEC and financial incentives may be a good investment for malaria control. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0569-7) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-05 /pmc/articles/PMC4334415/ /pubmed/25653121 http://dx.doi.org/10.1186/s12936-015-0569-7 Text en © Chen et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chen, Ingrid T
Aung, Tin
Thant, Hnin Nwe Nwe
Sudhinaraset, May
Kahn, James G
Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar
title Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar
title_full Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar
title_fullStr Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar
title_full_unstemmed Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar
title_short Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar
title_sort cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in myanmar
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334415/
https://www.ncbi.nlm.nih.gov/pubmed/25653121
http://dx.doi.org/10.1186/s12936-015-0569-7
work_keys_str_mv AT cheningridt costeffectivenessanalysisofmalariarapiddiagnostictestincentiveschemesforinformalprivatehealthcareprovidersinmyanmar
AT aungtin costeffectivenessanalysisofmalariarapiddiagnostictestincentiveschemesforinformalprivatehealthcareprovidersinmyanmar
AT thanthninnwenwe costeffectivenessanalysisofmalariarapiddiagnostictestincentiveschemesforinformalprivatehealthcareprovidersinmyanmar
AT sudhinarasetmay costeffectivenessanalysisofmalariarapiddiagnostictestincentiveschemesforinformalprivatehealthcareprovidersinmyanmar
AT kahnjamesg costeffectivenessanalysisofmalariarapiddiagnostictestincentiveschemesforinformalprivatehealthcareprovidersinmyanmar